ПРОДУКЦИЯ ФАКТОРОВ РОСТА И ДЕСКВАМАЦИЯ ЭНДОТЕЛИОЦИТОВ В СЕРДЦЕ ПРИ ИШЕМИЧЕСКОЙ КАРДИОМИОПАТИИ

oai:oai.kpccz.elpub.ru:article/1324Highlights Dysregulation of angiogenesis may be the pathogenetic factor of ischemic cardiomyopathy (ICMP). Aim. To determine the content of growth factors and desquamated endothelial cells (DEC) in the blood from the coronary sinus and ulnar vein in association with the number of progenitor endothelial cells (PEC) in the blood from the ulnar vein in patients with coronary heart disease (CHD), suffering and not suffering from ICMP.Methods. The study included 30 patients with ICMР and 22 patients with CHD, and 18 healthy donors. The content of DEC (CD45–CD146+) was determined in blood from the cubital vein (peripheral) and coronary sinus, and the content of DEC (CD14+CD34+VEGFR2+) was determined in peripheral blood by flow cytometry (antibodies “BD Biosciences”, USA). The concentrations of VEGF-A, VEGF-B, PDGF, SDF-1, SCF, FGF-1, TGF-β1 in blood plasma from both locations were evaluated by multiplex analysis (set “Cloud-Clone Corp.”, USA).Results. The content of DEC in peripheral blood was elevated in patients with CHD of both groups, and in patients with ICMP in sinus blood was higher than in peripheral. At the same time, in patients with CHD without cardiomyopathy, an excess of PEC and SDF-1 in the blood from the ulnar vein was established in combination with an increase in the concentration of PDGF and a decrease in the content of VEGF-B in the blood from the coronary sinus relative to the parameters of systemic blood flow. In patients with ICMP, these changes were not detected, but there was an increase in the concentration of TGF-β1 in sinus blood compared with peripheral blood. Regardless of the presence of ICMP, the concentration of SCF, FGF-1, VEGF-A in the blood from the ulnar vein corresponded to the norm and that in sinus blood; the content of VEGF-A in the coronary bloodstream exceeded its systemic level.Conclusion. In patients with ICMP, desquamation of the coronary vascular endothelium is enhanced against the background of violations of its repair processes due to insufficient (relative to CHD without cardiomyopathy) mobilization of PEC from the bone marrow due to the absence of an excess of SDF-1 in the blood and their insufficient homing into the myocardium due to weak PDGF production in the heart.Основные положенияПатогенетическим фактором ишемической кардиомиопатии может быть нарушение регуляции ангиогенеза. Цель. Определить содержание факторов роста и десквамированных эндотелиальных клеток (ДЭК) в крови из коронарного синуса и локтевой вены в ассоциации с численностью прогениторных эндотелиальных клеток (ПЭК) в крови из локтевой вены у больных ишемической болезнью сердца (ИБС), страдающих и не страдающих ишемической кардиомиопатией (ИКМП).Материалы и методы. В исследование включили 30 пациентов с ИБС и ИКМП, 22 больных ИБС без ИКМП, 18 здоровых доноров. Содержание ДЭК (CD45–CD146+) определяли в крови из локтевой вены (периферическая) и коронарного синуса (синусовая), а содержание ПЭК (CD14+CD34+VEGFR2+) – в периферической крови методом проточной цитофлуориметрии (антитела BD Biosciences, США). В плазме обоих образцов крови оценивали концентрацию VEGF-A, VEGF-B, PDGF, SDF-1, SCF, FGF-1, TGF-β1 методом мультиплексного анализа (набор Cloud-Clone Corp., США).Результаты. Содержание ДЭК в периферической крови было повышенным у больных ИБС обеих групп, а в синусовой крови у пациентов с ИКМП было выше, чем в периферической. У больных ИБС без ИКМП установлен избыток ПЭК и SDF-1 в крови из локтевой вены в сочетании с увеличением концентрации PDGF и снижением содержания VEGF-В в крови из коронарного синуса относительно параметров системного кровотока. У пациентов с ИКМП данные изменения не выявлены, но отмечен рост концентрации TGF-β1 в синусовой крови по сравнению с периферической. Вне зависимости от ИКМП концентрация SCF, FGF-1, VEGF-А в крови из локтевой вены соответствовала норме и таковой в синусовой крови; содержание VEGF-А в коронарном кровотоке превышало системный уровень.Заключение. При ИКМП усилена десквамация эндотелия коронарных сосудов на фоне нарушений его репарации за счет недостаточной (относительно ИБС без ИКМП) мобилизации ПЭК из костного мозга ввиду отсутствия избытка SDF-1 в крови и недостаточного их хоминга в миокард вследствие слабой продукции PDGF в сердце

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected